Is 5-Amino-1MQ Legal? FDA Status and Regulations Explained (2026)
If you're researching 5-Amino-1MQ legality, you're probably trying to answer a pretty specific question: can your doctor prescribe it, can a pharmacy make it, and is the product you found online going to get you — or your provider — into trouble? The short answer is that 5-Amino-1MQ occupies a genuinely grey zone in US law, and the details matter enormously depending on how you're trying to access it.
Here's what you need to know upfront: 5-Amino-1MQ is not FDA-approved for any clinical indication as of March 2026.[1] It's classified as a research-only compound, which means its legal use in the United States is formally limited to laboratory and preclinical research settings. That doesn't mean it's a controlled substance — it isn't scheduled under the Controlled Substances Act — but it does mean that selling it as a treatment, prescribing it as a drug, or marketing it for human use sits outside the bounds of current US law. The grey market for this compound is real, active, and not without legal risk.
Key Takeaways
- 5-Amino-1MQ is not FDA-approved for any human indication and carries a "research use only" designation as of March 2026.
- It is not a DEA-scheduled controlled substance, so possession alone doesn't trigger criminal liability the way a Schedule I drug would — but selling or marketing it for human use does violate federal law.
- Compounding pharmacies cannot legally produce 5-Amino-1MQ for patient use because it has not been placed on the FDA's 503A or 503B bulk drug substance lists.
- Prescribing 5-Amino-1MQ is not "off-label prescribing" in the conventional sense — it's prescribing an unapproved drug, which carries distinct legal and liability implications for providers.
- Products sold online as "research use only" are not a legal workaround for human use — the FDA evaluates intended use, not labeling, when determining whether a product is being marketed as a drug.
- The FDA has taken enforcement action against companies marketing unapproved research compounds for human use; consult FDA.gov for current enforcement activity.
Regulatory Status at a Glance
| Category | Status | Detail |
|---|---|---|
| FDA Approval | Not approved | No approved indication for any human use as of March 2026 |
| FDA Compounding (503A) | Not listed | Absent from the 503A bulk drug substance list; compounding for patients not permitted |
| FDA Compounding (503B) | Not listed | Absent from the 503B outsourcing facility list |
| DEA Scheduling | Not scheduled | Not listed under the Controlled Substances Act |
| Prescription Availability | Not available by Rx | No legal prescription pathway exists in the US at this time |
| Research Use | Permitted | Available for legitimate laboratory and preclinical research |
| International (EU/EMA) | Not approved | No EMA marketing authorization |
| International (UK MHRA) | Not approved | No MHRA marketing authorization |
| International (Australia TGA) | Not approved | Not listed on the Australian Register of Therapeutic Goods |
| International (Canada) | Not approved | Not authorized by Health Canada |
Current FDA Status
5-Amino-1MQ has no FDA approval for any clinical indication.[1] The compound — formally a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT) — has not completed the Investigational New Drug (IND) application process, has not entered Phase I human safety trials, and does not have a New Drug Application (NDA) or Biologics License Application (BLA) on file with the FDA.[2]
What it does have is a growing body of preclinical data. Research published in peer-reviewed journals has demonstrated that 5-Amino-1MQ inhibits NNMT with measurable selectivity, increasing NAD⁺ salvage pathway flux in cell culture and rodent models.[3] That's genuinely interesting science. But preclinical data and FDA approval are separated by a decade-long, multi-billion-dollar process that 5-Amino-1MQ has not begun.
The FDA's position is straightforward: a compound intended for human use that hasn't been approved through the NDA or BLA pathway is an unapproved new drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act).[2] Marketing, distributing, or selling such a compound for human therapeutic use is illegal, regardless of how the product is labeled.
The "research only" classification means exactly what it says. The compound can be legally synthesized, sold, and used within a legitimate research context — university laboratories, pharmaceutical R&D settings, and licensed research institutions. It cannot legally be sold to consumers for self-administration, prescribed by physicians as a treatment, or compounded by pharmacies for patient dispensing.
Compounding Status
This is where a lot of people get confused, so let's be precise.
Under Section 503A of the FD&C Act, licensed pharmacists can compound drugs for individual patients based on a valid prescription — but only using bulk drug substances that appear on an FDA-approved list, or that are components of FDA-approved drugs, or that appear in the United States Pharmacopeia (USP) or National Formulary (NF).[2]
5-Amino-1MQ appears on none of these lists. The FDA's 503A bulk drug substance list (sometimes called the "Category 1" list for nominated substances under evaluation) does not include 5-Amino-1MQ as of March 2026. It has not been nominated through the formal FDA docket process for inclusion, and it has not received a Category 1 (permissible pending review) or Category 2 (not permissible) designation — it simply hasn't entered that pipeline at all.[1]
The 503B outsourcing facility pathway, which governs larger-scale compounding operations, has the same limitation. Without an FDA listing, a 503B facility has no legal basis to produce 5-Amino-1MQ for patient use.
What this means practically: if a compounding pharmacy offers you 5-Amino-1MQ, they're operating outside the bounds of federal compounding law. That's not a minor technicality — it's a meaningful legal and safety concern. Compounding oversight exists specifically to ensure that products dispensed to patients meet quality, sterility, and potency standards. Products sourced outside that framework carry no such assurances.
For comparison, BPC-157 and TB-500 are other research compounds navigating similar compounding gray areas — you can read more about their specific regulatory status in their respective profiles on MyPeptideMatch.
Enforcement Actions
The FDA has taken enforcement action against companies marketing unapproved research compounds — including NNMT-related and metabolic research chemicals — for human use. Consult FDA.gov and the FDA's MedWatch program for current enforcement activity related to 5-Amino-1MQ specifically.[1]
What the FDA's enforcement pattern looks like in this category, generally:
The agency typically targets sellers and distributors rather than individual buyers. Warning letters are the most common first step, followed by injunctions, product seizures, and, in egregious cases, criminal referrals to the Department of Justice. The FTC has also taken action against companies making unsubstantiated health claims about unapproved compounds sold online.
The clearest enforcement risk sits with:
- Vendors selling 5-Amino-1MQ as a "supplement" or "metabolic support" product for human use
- Clinics prescribing or dispensing it without a legal compounding pathway
- Online retailers shipping it internationally while marketing it for therapeutic purposes
Individual patients who purchase research compounds for personal use occupy a lower enforcement priority, but that doesn't mean zero risk — and it certainly doesn't mean the products they're receiving are safe, accurately dosed, or what the label says they are.
Prescription vs. Over-the-Counter vs. Research Use
Let's map out the three pathways people actually try to use — and what's legal about each.
Prescription: There is currently no legal prescription pathway for 5-Amino-1MQ in the United States. A physician cannot write a valid prescription for a compound that isn't FDA-approved and isn't on the 503A/503B compounding lists. A prescription written for 5-Amino-1MQ has no legal mechanism for fulfillment at a licensed US pharmacy.
Over-the-counter: 5-Amino-1MQ is not approved as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994.[4] It doesn't meet the definition of a dietary ingredient, and marketing it as a supplement while making structure/function or disease claims would draw FDA scrutiny. Some vendors sell it in capsule form online — that doesn't make it legal; it makes it an unapproved drug sold without authorization.
Research use: This is the only legally clear pathway. Purchasing 5-Amino-1MQ as a research chemical — for use in a laboratory, by a qualified researcher, for non-human research purposes — is legal. The compound is available from research chemical suppliers who sell it with "not for human use" labeling. The legal protection here is real, but it's narrow: the moment the intended use shifts to human administration, the "research use only" label becomes legally irrelevant.
The "research use only" label is not a loophole. The FDA evaluates intended use based on the totality of circumstances — how a product is marketed, who's buying it, how it's dosed, and what the seller knows about how customers are using it. A vendor selling 5-Amino-1MQ in 50mg capsules through a website with testimonials about fat loss and metabolic benefits isn't protected by a "research use only" disclaimer.[2]
Gray market products and international purchasing carry compounding risks of their own. Products ordered from overseas suppliers — particularly those based in China or Eastern Europe — are not subject to FDA manufacturing standards. Customs enforcement for personal-use quantities of non-scheduled research chemicals is inconsistent, but importation of unapproved drugs for human use violates federal law regardless of the quantity.
What "Off-Label" Actually Means
This distinction matters, and it's one that even some clinicians get wrong.
"Off-label prescribing" refers to a physician using an FDA-approved drug for an indication, population, or dosage that isn't in the approved labeling. It's legal, common (roughly 20% of all prescriptions in the US are off-label),[5] and covered by established medical-legal doctrine. A physician prescribing metformin for weight management in non-diabetic patients, for example, is practicing off-label prescribing.
That framework does not apply to 5-Amino-1MQ. Because 5-Amino-1MQ has never received FDA approval for any indication, prescribing it isn't off-label use — it's prescribing an unapproved new drug. These are legally distinct categories with different implications.
For providers, the liability calculus is meaningfully different. Off-label prescribing of an approved drug is supported by a body of safety data from the approval process. Prescribing an unapproved compound with only preclinical data means your patient has no FDA-validated safety profile, no established dosing range from human trials, and no pharmacovigilance system tracking adverse events. If a patient is harmed, the malpractice exposure is significant — and professional licensing boards in most states take a dim view of prescribing unapproved compounds outside of a formal research protocol.
Clinics offering 5-Amino-1MQ as a clinical service should be a red flag, not a selling point. You can find guidance on identifying legitimate peptide therapy providers in our clinic finder and our guide to evaluating peptide therapy clinics.
State-Level Variations
Federal law sets the floor here, but state medical and pharmacy boards add their own layer of oversight.
State pharmacy boards have the authority to discipline pharmacists and pharmacies that compound substances outside the 503A framework. Several state boards — including those in California, Texas, and Florida — have issued guidance explicitly prohibiting compounding of substances not on the FDA's approved bulk drug substance lists. A pharmacy compounding 5-Amino-1MQ in those states faces both federal and state regulatory exposure.
State medical boards can sanction physicians for prescribing unapproved compounds without adequate scientific basis or informed consent documentation. The standard of care analysis varies by state, but prescribing a compound with no human safety data and no FDA approval pathway is difficult to defend before most state boards.
Telemedicine prescribing adds another variable. The Ryan Haight Act and its post-COVID modifications govern controlled substance prescribing via telemedicine, but 5-Amino-1MQ isn't a controlled substance. State telemedicine laws still apply, however, and prescribing an unapproved compound to a patient you've never examined in person raises both legal and ethical concerns that vary by jurisdiction.
If you're working with a telehealth provider who's offering 5-Amino-1MQ, ask them directly: what is the legal basis for this prescription, which pharmacy is filling it, and is that pharmacy on the FDA's 503A or 503B registered list? If they can't answer those questions clearly, that's your answer.
International Status
The picture outside the US is consistent: 5-Amino-1MQ has no marketing authorization in any major regulatory jurisdiction as of March 2026.
European Union (EMA): No marketing authorization from the European Medicines Agency. Research use is permitted under applicable national research regulations, but clinical or commercial distribution for human use is not authorized.[1]
United Kingdom (MHRA): No UK marketing authorization. Post-Brexit, the MHRA operates independently of the EMA, but the outcome here is the same — no approved indication, no legal clinical use.
Australia (TGA): Not listed on the Australian Register of Therapeutic Goods (ARTG). The TGA's Special Access Scheme (SAS) theoretically allows access to unapproved therapeutic goods in specific clinical circumstances, but 5-Amino-1MQ has not been granted SAS status.
Canada (Health Canada): Not authorized under the Food and Drugs Act. Canada's Special Access Program (SAP) exists for unapproved drugs in serious or life-threatening conditions, but no SAP authorization for 5-Amino-1MQ has been reported.
Purchasing 5-Amino-1MQ from international online vendors and importing it into the US doesn't circumvent FDA jurisdiction. The FDA has authority over drugs imported for personal use, and while enforcement of small personal-use shipments is inconsistent, the legal risk is real and the quality risk is arguably greater.
What This Means for Patients
If you're a patient who's heard about 5-Amino-1MQ's potential effects on NAD⁺ metabolism, cellular aging, or body composition — and you're trying to figure out whether you can access it through a legitimate medical channel — here's the honest answer: not legally, not right now.
That doesn't mean you're out of options. It means you should be asking better questions when a clinic or online vendor suggests otherwise.
Red flags to watch for:
- A clinic offering 5-Amino-1MQ as a standard treatment without disclosing its unapproved status
- A "compounding pharmacy" filling a prescription for 5-Amino-1MQ (no legal US pharmacy can do this)
- Online vendors selling capsules or powders labeled "for research use only" while clearly marketing them for human metabolic or anti-aging purposes
- Providers who can't name the pharmacy, can't provide a Certificate of Analysis (CoA), or can't explain the legal basis for prescribing
Questions to ask any provider offering novel compounds:
- Is this compound FDA-approved, and if not, what is the legal basis for prescribing it?
- Which pharmacy is compounding this, and are they registered with the FDA as a 503A or 503B facility?
- What human safety data exists, and can I see the informed consent documentation?
- What adverse event reporting process is in place if I experience a reaction?
To report suspicious sellers or products, use the FDA's MedWatch Safety Reporting Portal at FDA.gov/safety/medwatch or call 1-800-FDA-1088.
Legal Alternatives
If you're interested in the metabolic and longevity-related pathways that 5-Amino-1MQ targets — particularly NAD⁺ metabolism and cellular energy regulation — there are compounds with more established legal and safety profiles worth discussing with a qualified provider.
NAD⁺ precursors with clearer regulatory status:
- Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are available as dietary supplements and have human clinical trial data. They work upstream of the same NAD⁺ salvage pathway that 5-Amino-1MQ targets through NNMT inhibition, though via a different mechanism.
Peptides with established compounding pathways:
- Sermorelin is available through licensed compounding pharmacies and has a longer clinical history in the US.
- Ipamorelin and CJC-1295 are available through compounding pharmacies, though their regulatory status has evolved — check our updated profiles for current status.
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has the clearest legal status among growth hormone-related peptides.
For metabolic and body composition goals, FDA-approved options like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have robust Phase III clinical trial data and established legal prescribing pathways. Our clinic finder can connect you with providers who specialize in these therapies.
What the Evidence Does Not Show
The scientific literature on 5-Amino-1MQ is genuinely early-stage. Here's what remains unknown or unestablished:
No human pharmacokinetic data exists. Oral bioavailability, half-life in humans, volume of distribution, and metabolic clearance pathways have not been characterized in clinical studies. The dosing ranges circulating in online communities are extrapolated from rodent studies, not human trials.
No human safety data exists. Adverse effect profiles, drug-drug interactions, contraindications, and long-term safety have not been evaluated in any registered human trial as of March 2026.
The FDA's regulatory position may evolve. If a pharmaceutical company files an IND application for 5-Amino-1MQ and begins human trials, the regulatory landscape shifts. An approved IND would allow human research under controlled conditions but would not immediately create a prescription pathway for general clinical use.
The compounding pathway could open. If 5-Amino-1MQ is nominated to the FDA's 503A bulk drug substance list and receives a Category 1 designation (permissible while under review), licensed compounding pharmacies could potentially compound it for patients with a valid prescription. That process takes years and requires a formal petition to the FDA — it hasn't started.
International regulatory decisions could diverge from the US. If the EMA or another major regulatory body authorizes 5-Amino-1MQ for a specific indication, that could influence FDA timelines and create pressure for accelerated US review — but there's no indication that process is underway in any jurisdiction.
FAQ
Is 5-Amino-1MQ legal in the US?
For laboratory research, yes. For human use — whether self-administered, prescribed, or sold as a supplement — no. 5-Amino-1MQ is not FDA-approved, is not on the compounding bulk drug substance list, and has no legal clinical use pathway in the US as of March 2026.[1]
Can my doctor prescribe 5-Amino-1MQ?
Not legally. There's no FDA-approved indication, and there's no licensed compounding pharmacy that can fill a prescription for it. A physician who writes a prescription for 5-Amino-1MQ has no legal mechanism to have that prescription filled at any registered US pharmacy. Any clinic offering it as a prescribed treatment should be asked to explain — in writing — the legal basis for doing so.
Is it legal to buy 5-Amino-1MQ online?
Purchasing it as a research chemical from a supplier that sells to laboratories is technically legal if you're using it for genuine non-human research. Buying it to self-administer is a different matter — you'd be importing or purchasing an unapproved drug for human use, which violates the FD&C Act.[2] Enforcement against individual buyers is rare, but the legal exposure is real, and the quality of unregulated products is genuinely unknown.
What happens if I'm caught with 5-Amino-1MQ?
Because 5-Amino-1MQ is not a DEA-scheduled controlled substance, simple possession doesn't carry the criminal penalties associated with Schedule I or II drugs. The greater legal risk is on the seller's side. That said, importation of unapproved drugs for personal use violates federal law, and customs can seize shipments. Individual prosecution for personal possession is extremely uncommon, but it's not legally risk-free.
Is 5-Amino-1MQ a controlled substance?
No. As of March 2026, 5-Amino-1MQ is not listed under any schedule of the Controlled Substances Act and is not subject to DEA scheduling requirements.[1] This distinguishes it from compounds like peptide analogs that have been scheduled, but it doesn't make human use legal — it just means the legal framework is the FD&C Act rather than the CSA.
Can compounding pharmacies make 5-Amino-1MQ?
No. Compounding pharmacies operating under Section 503A or 503B of the FD&C Act can only use bulk drug substances that appear on the FDA's approved lists or that are components of FDA-approved drugs. 5-Amino-1MQ appears on neither list.[2] A pharmacy compounding it for patient use would be operating outside federal law.
Is "research use only" 5-Amino-1MQ legal?
For actual laboratory research, yes. For human self-administration dressed up in "research use only" packaging, no. The FDA looks at how a product is actually being used and marketed, not just what the label says. A vendor selling 5-Amino-1MQ capsules to consumers while marketing benefits like "metabolic enhancement" or "fat loss" isn't protected by a disclaimer, regardless of how the label reads.[2]
Has anyone been prosecuted for 5-Amino-1MQ?
The FDA has taken enforcement action against companies marketing unapproved research compounds for human use. For current and specific enforcement activity related to 5-Amino-1MQ, consult FDA.gov and the FDA's MedWatch program. We will not speculate about specific cases without confirmed public records.
Could 5-Amino-1MQ become legally available in the future?
Possibly, but it would require either FDA approval through the NDA process (which requires successful Phase I, II, and III clinical trials) or placement on the 503A compounding bulk drug substance list. Neither process is currently underway for 5-Amino-1MQ as of March 2026. The preclinical science is interesting enough that pharmaceutical investment in a formal IND application is conceivable, but timelines for drug development typically run 10–15 years from preclinical to approval.
What should I do if a clinic offers me 5-Amino-1MQ as a treatment?
Ask them to provide written documentation of the legal basis for prescribing it, the name and FDA registration status of the compounding pharmacy filling it, and the human safety data they're relying on. If they can't answer those questions clearly, that's a significant red flag. You can also verify whether a pharmacy is FDA-registered at FDA.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.
References
- U.S. Food and Drug Administration. "FDA Drug Databases and Online Resources." FDA.gov. Accessed March 2026. https://www.fda.gov/drugs/drug-approvals-and-databases
- U.S. Food and Drug Administration. "Human Drug Compounding." FDA.gov. Federal Food, Drug, and Cosmetic Act, Sections 503A and 503B. Accessed March 2026. https://www.fda.gov/drugs/guidance-regulation-drug-products/human-drug-compounding
- Kannt A, et al. "Association of Nicotinamide-N-Methyltransferase mRNA Expression in Human Adipose Tissue and the Plasma Concentration of Its Product, 1-Methylnicotinamide, with Measures of Obesity in Caucasian Subjects." Diabetologia. 2015;58(4):799-808. PMID: 25586651
- U.S. Food and Drug Administration. "Dietary Supplement Health and Education Act of 1994." FDA.gov. Accessed March 2026. https://www.fda.gov/food/dietary-supplements/dietary-supplement-health-and-education-act-1994-dshea
- Wittich CM, Burkle CM, Lanier WL. "Ten Common Questions (and Their Answers) About Off-label Drug Use." Mayo Clinic Proceedings. 2012;87(10):982-990. PMID: 22877654
Legal status last verified: March 2026. Regulatory classifications can change. This article reflects publicly available FDA guidance and federal law as of the publication date. Readers should verify current status directly with FDA.gov before making clinical or purchasing decisions.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, legal advice, or a recommendation to use any compound. 5-Amino-1MQ is not FDA-approved for human use. Do not begin, discontinue, or modify any treatment based on information in this article. Consult a licensed healthcare provider and, where appropriate, a licensed attorney familiar with pharmaceutical law before making any decisions about accessing or using unapproved compounds.
